1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Alvotech Finds A New Omalizumab Partner In Kashiv

Pair’s Alliance On Xolair Biosimilar Follows Terminated Collaboration With BiosanaPharma

 
• By Dave Wallace

After earlier this year revealing that it had dropped a collaboration with BiosanaPharma on a biosimilar omalizumab rival to Xolair, Alvotech has now announced a fresh licensing deal for development and commercialization of a version from Kashiv BioSciences.

Red and green Enter and Exit sign icons
Alvotech has entered a new omalizumab partnership after exiting a previous deal • Source: Shutterstock

Just months after announcing that it had terminated a global licensing deal with BiosanaPharma for a biosimilar rival to Novartis’s Xolair (omalizumab), Alvotech has announced a fresh alliance with Kashiv BioSciences for the firm’s own ADL018 proposed omalizumab biosimilar.

Key Takeaways:

  • Alvotech has struck a licensing deal with Kashiv Biosciences for an omalizumab biosimilar

  • The collaboration comes after Alvotech earlier this year terminated a previous omalizumab alliance with BiosanaPharma

Also referred to by Alvotech under the codename AVT23 – the same codename used by the firm for the BiosanaPharma BP001 candidate before the deal was terminated – Kashiv’s version of the asthma, rhinosinusitis and spontaneous urticaria treatment is currently in clinical development,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.